Journal
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 10, Issue 2, Pages 671-678Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2015.2526
Keywords
extensive-stage small-cell lung cancer; 3-dimensional conformal thoracic radiotherapy; chemotherapy; efficacy
Categories
Ask authors/readers for more resources
The aim of the present study was to evaluate the effect of 3-dimensional conformal thoracic radiotherapy (TRT) on extensive-stage small-cell lung cancer (ES-SCLC). A total of 165 patients with ES-SCLC were enrolled in the present study, including 82 patients receiving chemotherapy combined with TRT (the ChT/TRT group) and 83 patients receiving chemotherapy alone (the ChT group). The overall survival (OS) and progression-free survival (PFS) rates were compared between the ChT/TRT and ChT groups, and the prognostic factors for OS rate were identified. It was found that the patients had a median OS time of 15 months, and 2-and 5-year OS rates of 31.5 and 2.4%, respectively. The 2-and 5-year OS rates were 35.3 and 2.4% in the ChT/TRT group, and 14.5 and 2.4% in the ChT group, respectively (P<0.05). The 1- and 2-year PFS rates were 35.4 and 6.0% in the ChT/TRT group, and 20.5 and 6.0% in the ChT group, respectively (P< 0.05). The median PFS was 11 months in the 20 patients receiving TRT at 45 Gy/30 fractions twice daily, and 9 months in the 22 patients receiving TRT at 60 Gy/30 fractions daily (P= 0.043). Multivariate analysis revealed that receiving >= 4 cycles of chemotherapy (P= 0.001) and TRT (P= 0.008) were favorable prognostic factors for OS. It was concluded that the addition of TRT improves the OS and PFS rates of patients with ES-SCLC, and TRT administration at 45 Gy/30 fractions twice daily is feasible and tolerable for the treatment of ES-SCLC. Thus, TRT and receiving >= 4 cycles of chemotherapy are independent, favorable prognostic factors for OS in patients with ES-SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available